NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00144378,Irinotecan Versus Only Best Supportive Care for Gastric Cancer,https://clinicaltrials.gov/study/NCT00144378,,COMPLETED,"The median survival at progression after first-line chemotherapy for metastatic gastric cancer is about 2.5 months. There are no data which a possible benefit of second line therapy. for this reason a trial which investigates a possible benefit or chemotherapy compared to best supportive care as second line treatment is urgently necessary.

Irinotecan shows response rates of 20% in the first line therapy with high rates od disease stabilization. There are few trials investigating irinotecan in the second line setting. Response rates of 20% are reported in tis setting. Irinotecan is supplied without costs from the company Pfizer.",NO,Stomach Neoplasm|Neoplasm Metastasis,DRUG: Irinotecan,median survival,"quality of life, response rates, time to tumor progression, toxicity",,"Charite University, Berlin, Germany",,ALL,"ADULT, OLDER_ADULT",PHASE3,44,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE|Primary Purpose: ",irinotecan vs. bsc,2002-10,,,2005-09-05,,2007-04-18,"Charité,Universitätsmedizin Berlin, Campus Virchow Klinikum, Dep. orf Hematology and Oncology,, Berlin, Germany",
